GlassScriptPhysician profile
Lawrence A Adjei
NPI 1689637134
$18,762.25
in general payments reported to CMS, 2019-2025
59 companies · $2,272 in 2025
The $2,272 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,322 · 2020: $2,419 · 2021: $3,186 · 2022: $2,911 · 2023: $3,052 · 2024: $2,601 · 2025: $2,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,909 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,909.22 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,848.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,840.89 | 2020-2025 | Vraylar, Linzess, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,545.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,306.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,195.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $757.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $665.36 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Axsome Therapeutics, INC. | $618.60 | 2023-2025 | Sunosi, Auvelity |
| Amgen INC. | $594.13 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Allergan, INC. | $579.17 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $553.07 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $530.73 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $524.16 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $493.58 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $462.14 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Adjei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.